Tregs CD25 CXCL9 in Vitiligo
Launched by ASSIUT UNIVERSITY · Oct 3, 2022
Trial Information
Current as of July 04, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial, titled "Tregs CD25 CXCL9 in Vitiligo," is studying how certain immune cells and proteins in the blood might help us understand the activity of vitiligo, a skin condition that causes loss of pigmentation. The researchers want to see if measuring these immune cells and proteins can give us better insight into how the disease is progressing in patients with non-segmental vitiligo.
To participate in this study, individuals must be diagnosed with non-segmental vitiligo and be between the ages of 18 and 75. However, people who have recently received systemic treatments or have other autoimmune diseases like rheumatoid arthritis or lupus will not be eligible to join. If you qualify, you can expect to provide blood samples for testing. This research is still in the planning stages, so the study is not yet recruiting participants. Your involvement could contribute to important discoveries about vitiligo and help improve understanding and treatment options for this condition.
Gender
ALL
Eligibility criteria
- • Inclusion Criteria:The patients will be enrolled in the study if they have :-
- • Non segmental vitiligo.
- Exclusion Criteria:
- The following patients were excluded from this study:
- • Patients receiving systemic treatment in the last two months.
- • Patients with any autoimmune disease, such as rheumatoid arthritis. inflammatory bowel disease, psoriasis, or systemic lupus erythematosus; patients with type 1 diabetes mellitus.
- • Patients with any thyroid and/or neoplastic diseases.
About Assiut University
Assiut University, a prominent academic institution located in Egypt, is dedicated to advancing medical research and clinical trials that enhance healthcare outcomes. With a strong emphasis on innovation and collaboration, the university engages in a wide array of clinical studies across various disciplines, aiming to contribute valuable insights into disease prevention, diagnosis, and treatment. Assiut University's commitment to ethical research practices and rigorous scientific methodology ensures the integrity and reliability of its clinical trials, ultimately benefiting both the local community and the global medical landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials